ESMO 2017 | Durvalumab: the new standard of care for NSCLC?

Johan Vansteenkiste

Johan Vansteenkiste, MD, PhD, from the University Hospitals Leuven, Leuven, Belgium, discussesthe PACIFIC trial (NCT02125461) at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Non-small cell lung cancer (NSCLC) patients are typically treated with a combination of chemotherapy and radiotherapy, however a significant number of these patients relapse. The PACIFC study investigated the efficacy of durvalumab compared with a placebo as consolidation therapy after chemotherapy for stage 3 NSCLC. The results showed a significant improvement in progression free survival, as well as an impressive hazard ratio.

Share this video